Furthermore, a recent phase-2 clinical study in patients with new-onset T1D showed that the pharmacological inhibition of the Janus kinases (JAK) 1 and 2, downstream components of the IFN signalling, preserves beta cell function as estimated by mixed-meal–stimulated mean C-peptide level21. Here, IFNA1 is linked to type 1 diabetes mellitus.